I agree that this site is using cookies. You can find further informations here.
X
Frustaci, A. M.
~ 200  results:
Search for persons X
?
1

EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PH..:

Frustaci, A. M. ; Montillo, M. ; Rossi, D....
Hematological Oncology.  41 (2023)  S2 - p. 62-63 , 2023
Link: https://doi.org/10.1002/..
 
?
2

P660: SEROLOGIC RESPONSE TO THE SECOND AND THIRD DOSE OF TH..:

Mauro, F. R. ; Giannarelli, D. ; Galluzzo, C....
HemaSphere.  6 (2022)  - p. 558-559 , 2022
Link: https://doi.org/10.1097/..
 
?
3

P659: IBRUTINIB IN OVER-EIGHTIES PATIENTS WITH CHRONIC LYMP..:

Reda, G. ; Mattiello, V. ; Frustaci, A. M....
HemaSphere.  6 (2022)  - p. 557-558 , 2022
Link: https://doi.org/10.1097/..
 
?
4

MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CL..:

Frustaci, A. M. ; Tedeschi, A. ; Zinzani, P. L....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
5

ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS ..:

Terzi di Bergamo, L ; Forestieri, G ; Loh, J. W...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
6

IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RI..:

Condoluci, A. ; Terzi‐di‐Bergamo, L. ; Forestieri, G....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
7

A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II TRIAL EVA..:

Montillo, M. ; Rossi, D. ; Zucca, E....
Hematological Oncology.  37 (2019)  S2 - p. 557-558 , 2019
Link: https://doi.org/10.1002/..
 
?
8

The anatomical foundations of acquired reading disorders: A..:

Ripamonti, E. ; Aggujaro, S. ; Molteni, F....
Brain and Language.  134 (2014)  - p. 44-67 , 2014
Link: https://doi.org/10.1016/..
 
?
9

The Anatomical Foundations of Acquired Reading Disorders:

Ripamonti, E. ; Aggujaro, S. ; Molteni, F....
Procedia - Social and Behavioral Sciences.  61 (2012)  - p. 302-303 , 2012
Link: https://doi.org/10.1016/..
 
?
10

P473 Corticosteroid-free clinical remission rates with guse..:

D'Haens, G ; Afzali, A ; Filip, R...
Journal of Crohn's and Colitis.  17 (2023)  Supplement_1 - p. i601-i602 , 2023
Link: https://doi.org/10.1093/..
 
?
11

OP24 Clinical efficacy and safety of guselkumab maintenance..:

Danese, S ; Panaccione, R ; Rubin, D T...
Journal of Crohn's and Colitis.  16 (2022)  Supplement_1 - p. i026-i027 , 2022
Link: https://doi.org/10.1093/..
 
?
12

OP28 The effect of guselkumab induction therapy on early cl..:

Danese, S ; Sandborn, W J ; Feagan, B G...
Journal of Crohn's and Colitis.  15 (2021)  Supplement_1 - p. S027-S028 , 2021
Link: https://doi.org/10.1093/..
 
?
13

Analgesic efficacy of fulranumab in patients with painful d..:

Wang, H. ; Romano, G. ; Frustaci, M.E....
Journal of the Neurological Sciences.  333 (2013)  - p. e522-e523 , 2013
Link: https://doi.org/10.1016/..
 
?
14

Peripheral nerve safety measures in a multicenter, double-b..:

Polydefkis, M. ; Wang, H. ; Romano, G....
Journal of the Neurological Sciences.  333 (2013)  - p. e434 , 2013
Link: https://doi.org/10.1016/..
 
?
15

Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vu..:

Mauro, Francesca R. ; Giannarelli, Diana ; Galluzzo, Clementina M....
Cancers.  15 (2023)  11 - p. 2993 , 2023
Link: https://doi.org/10.3390/..
 
1-15